Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients

Claire Dendle, Rhonda L. Stuart, Kevan R. Polkinghorne, Anne Balloch, John Kanellis, Johnathan Ling, Megan Kummrow, Chelsea Moore, Karin Thursky, Jim Buttery, Kim Mulholland, Poh Yi Gan, Stephen Holdsworth, William R. Mulley

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Background: Conjugated pneumococcal vaccine is recommended for kidney transplant recipients, however, their immunogenicity and potential to trigger allograft rejection though generation of de novo anti-human leukocyte antigen antibodies has not been well studied. Methods: Clinically stable kidney transplant recipients participated in a prospective cohort study and received a single dose of 13-valent conjugate pneumococcal vaccine. Anti-pneumococcal IgG was measured for the 13 vaccine serotypes pre and post vaccination and functional anti-pneumococcal IgG for 4 serotypes post vaccination. Anti-human leukocyte antigen antibodies antibodies were measured before and after vaccination. Kidney transplant recipients were followed clinically for 12 months for episodes of allograft rejection or invasive pneumococcal disease. Results: Forty-five kidney transplant recipients participated. Median days between pre and post vaccination serology was 27 (range 21-59). Post vaccination, there was a median 1.1 to 1.7-fold increase in anti-pneumococcal IgG antibody concentrations for all 13 serotypes. Kidney transplant recipients displayed a functional antibody titer ≥1:8 for a median of 3 of the 4 serotypes. Post vaccination, there were no de novo anti-human leukocyte antigen antibodies, no episodes of biopsy proven rejection or invasive pneumococcal disease. Conclusion: A single dose of 13-valent conjugate pneumococcal vaccine elicits increased titers and breadth of functional anti-pneumococcal antibodies in kidney transplant recipients without stimulating rejection or donor-specific antibodies.

Original languageEnglish
Article numbere12866
Number of pages9
JournalTransplant Infectious Disease
Volume20
Issue number2
DOIs
Publication statusPublished - 1 Apr 2018

Keywords

  • kidney transplantation
  • luminex technology
  • pneumococcal antigen
  • serotype-specific antibody response

Cite this

@article{2d847dbccf0442d0bac35ee766959a8c,
title = "Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients",
abstract = "Background: Conjugated pneumococcal vaccine is recommended for kidney transplant recipients, however, their immunogenicity and potential to trigger allograft rejection though generation of de novo anti-human leukocyte antigen antibodies has not been well studied. Methods: Clinically stable kidney transplant recipients participated in a prospective cohort study and received a single dose of 13-valent conjugate pneumococcal vaccine. Anti-pneumococcal IgG was measured for the 13 vaccine serotypes pre and post vaccination and functional anti-pneumococcal IgG for 4 serotypes post vaccination. Anti-human leukocyte antigen antibodies antibodies were measured before and after vaccination. Kidney transplant recipients were followed clinically for 12 months for episodes of allograft rejection or invasive pneumococcal disease. Results: Forty-five kidney transplant recipients participated. Median days between pre and post vaccination serology was 27 (range 21-59). Post vaccination, there was a median 1.1 to 1.7-fold increase in anti-pneumococcal IgG antibody concentrations for all 13 serotypes. Kidney transplant recipients displayed a functional antibody titer ≥1:8 for a median of 3 of the 4 serotypes. Post vaccination, there were no de novo anti-human leukocyte antigen antibodies, no episodes of biopsy proven rejection or invasive pneumococcal disease. Conclusion: A single dose of 13-valent conjugate pneumococcal vaccine elicits increased titers and breadth of functional anti-pneumococcal antibodies in kidney transplant recipients without stimulating rejection or donor-specific antibodies.",
keywords = "kidney transplantation, luminex technology, pneumococcal antigen, serotype-specific antibody response",
author = "Claire Dendle and Stuart, {Rhonda L.} and Polkinghorne, {Kevan R.} and Anne Balloch and John Kanellis and Johnathan Ling and Megan Kummrow and Chelsea Moore and Karin Thursky and Jim Buttery and Kim Mulholland and Gan, {Poh Yi} and Stephen Holdsworth and Mulley, {William R.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1111/tid.12866",
language = "English",
volume = "20",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",
number = "2",

}

Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients. / Dendle, Claire; Stuart, Rhonda L.; Polkinghorne, Kevan R.; Balloch, Anne; Kanellis, John; Ling, Johnathan; Kummrow, Megan; Moore, Chelsea; Thursky, Karin; Buttery, Jim; Mulholland, Kim; Gan, Poh Yi; Holdsworth, Stephen; Mulley, William R.

In: Transplant Infectious Disease, Vol. 20, No. 2, e12866, 01.04.2018.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Seroresponses and safety of 13-valent pneumococcal conjugate vaccination in kidney transplant recipients

AU - Dendle, Claire

AU - Stuart, Rhonda L.

AU - Polkinghorne, Kevan R.

AU - Balloch, Anne

AU - Kanellis, John

AU - Ling, Johnathan

AU - Kummrow, Megan

AU - Moore, Chelsea

AU - Thursky, Karin

AU - Buttery, Jim

AU - Mulholland, Kim

AU - Gan, Poh Yi

AU - Holdsworth, Stephen

AU - Mulley, William R.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background: Conjugated pneumococcal vaccine is recommended for kidney transplant recipients, however, their immunogenicity and potential to trigger allograft rejection though generation of de novo anti-human leukocyte antigen antibodies has not been well studied. Methods: Clinically stable kidney transplant recipients participated in a prospective cohort study and received a single dose of 13-valent conjugate pneumococcal vaccine. Anti-pneumococcal IgG was measured for the 13 vaccine serotypes pre and post vaccination and functional anti-pneumococcal IgG for 4 serotypes post vaccination. Anti-human leukocyte antigen antibodies antibodies were measured before and after vaccination. Kidney transplant recipients were followed clinically for 12 months for episodes of allograft rejection or invasive pneumococcal disease. Results: Forty-five kidney transplant recipients participated. Median days between pre and post vaccination serology was 27 (range 21-59). Post vaccination, there was a median 1.1 to 1.7-fold increase in anti-pneumococcal IgG antibody concentrations for all 13 serotypes. Kidney transplant recipients displayed a functional antibody titer ≥1:8 for a median of 3 of the 4 serotypes. Post vaccination, there were no de novo anti-human leukocyte antigen antibodies, no episodes of biopsy proven rejection or invasive pneumococcal disease. Conclusion: A single dose of 13-valent conjugate pneumococcal vaccine elicits increased titers and breadth of functional anti-pneumococcal antibodies in kidney transplant recipients without stimulating rejection or donor-specific antibodies.

AB - Background: Conjugated pneumococcal vaccine is recommended for kidney transplant recipients, however, their immunogenicity and potential to trigger allograft rejection though generation of de novo anti-human leukocyte antigen antibodies has not been well studied. Methods: Clinically stable kidney transplant recipients participated in a prospective cohort study and received a single dose of 13-valent conjugate pneumococcal vaccine. Anti-pneumococcal IgG was measured for the 13 vaccine serotypes pre and post vaccination and functional anti-pneumococcal IgG for 4 serotypes post vaccination. Anti-human leukocyte antigen antibodies antibodies were measured before and after vaccination. Kidney transplant recipients were followed clinically for 12 months for episodes of allograft rejection or invasive pneumococcal disease. Results: Forty-five kidney transplant recipients participated. Median days between pre and post vaccination serology was 27 (range 21-59). Post vaccination, there was a median 1.1 to 1.7-fold increase in anti-pneumococcal IgG antibody concentrations for all 13 serotypes. Kidney transplant recipients displayed a functional antibody titer ≥1:8 for a median of 3 of the 4 serotypes. Post vaccination, there were no de novo anti-human leukocyte antigen antibodies, no episodes of biopsy proven rejection or invasive pneumococcal disease. Conclusion: A single dose of 13-valent conjugate pneumococcal vaccine elicits increased titers and breadth of functional anti-pneumococcal antibodies in kidney transplant recipients without stimulating rejection or donor-specific antibodies.

KW - kidney transplantation

KW - luminex technology

KW - pneumococcal antigen

KW - serotype-specific antibody response

UR - http://www.scopus.com/inward/record.url?scp=85044721463&partnerID=8YFLogxK

U2 - 10.1111/tid.12866

DO - 10.1111/tid.12866

M3 - Article

VL - 20

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

IS - 2

M1 - e12866

ER -